Patients With Bronchopulmonary Cancer
Conditions
Keywords
Hospital pharmacist, Pharmaceutical intervention, Chemotherapy / Immunotherapy /oral targeted therapy, Bronchopulmonary cancer
Brief summary
This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients (only questionnaires) with bronchopulmonary cancer treated by Chemotherapy and/or Immunotherapy or Oral targeted therapy. The primary objective of the study is to evaluate the number of unscheduled consultations/hospitalizations during 6 months.
Detailed description
Currently, several treatments can be used for bronchopulmonary cancers: targeted oral therapy (OCT), oral chemotherapy, iv chemotherapy, iv immunotherapy. These therapies are rather unknown to community pharmacy and induce several adverse effects and drug interactions. These treatments require collaboration between different professionals (community and hospital pharmacists) in order to allow follow up and security in patient supportive care. In our context of shortage of care staff, with a polymedicated and elderly population, we would like to assess the impact of hospital pharmacist in the drug management for patient with bronchopulmonary cancers treated by these therapies. Other French studies (Lille, Angers, Tours) involving hospital pharmacists were carried out and aimed to evaluate the number of pharmaceutical interventions carried out without assessing the impact on the patient. In addition, no study concerns the Center Val de Loire region. The aim of the study is to impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations. This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients with bronchopulmonary cancer. Participants will be included after being informed and after obtaining no opposition to participate. Data collection sheet will be performed by hospital pharmacist at inclusion. Participants will be treated according to standard of care for cancer treatment. An interview will be performed 1 month, 3 months and 6 months after inclusion between hospital pharmacist and participant to obtain information's on cancer treatments (questionnaires). These interviews will be performed by phone or when the patient comes to the hospital for a follow-up consultation as part of the treatment of his cancer (standard of care). A total of 60 participants will be included in this study based on 1) the number of patients received a novel cancer treatment in the center during 12 months and 2) considered eligibility criteria, pharmacist availability and patients consent.
Interventions
OTHERQuestionnaires and data collection sheet
Questionnaires
Sponsors
Centre Hospitalier Régional d'Orléans
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female ≥ 18 years 2. Patient without cognitive impairments 3. Patient with bronchopulmonary cancer 4. Patient treated by chemotherapy, immunotherapy or oral targeted therapy
Exclusion criteria
1. Patient informed and opposed to participate 2. Language barrier and lack of translator 3. Patient under guardianship, curatorship or deprived of liberty 4. Pregnant or breastfeeding women 5. Participation in any drug clinical drug trials 6. Patient with no insurance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations. | From enrolment to the end of the follow up phase (6 months) | Number of unscheduled consultations or hospitalizations during the follow up phase |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of hospital pharmacist (interview) on cancelled consultations/hospitalizations rate | From enrolment to the end of the follow up phase (6 months) | Number of cancelled consultations/hospitalizations |
| Impact of hospital pharmacist (interview) on treatment observance (number of dispensation) | From enrolment to the end of the follow up phase (6 months) | Number of treatment dispensation |
| Impact of hospital pharmacist (interview) on treatment observance (gap between dispensation) | From enrolment to the end of the follow up phase (6 months) | Gap between each treatment dispensation |
| Impact of hospital pharmacist (interview) on adverse effects | From enrolment to the end of the follow up phase (6 months) | Number of adverse effects (follow up phase of 6 months) |
| Impact of hospital pharmacist (interview) on adverse effects leading to interrupted or withdrawn treatment | From enrolment to the end of the follow up phase (6 months) | Number of adverse effects leading to interrupted or withdrawn treatment |
| Impact of hospital pharmacist on pharmaceutical intervention | From enrolment to the end of the follow up phase (6 months) | Number of pharmaceutical interventions (eg. inappropriate prescription, drug interactions) |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORCatherine DA VIOLANTE, Dr
CHU d'Orléans
Outcome results
None listed